Dr Frank Armstrong appointed as Non-executive Director

Newcells Biotech is pleased to announce that it has appointed Dr Frank Armstrong to its Board as a Non-executive Director.

“Attracting an executive of Frank’s proven track-record and expertise is another significant step forward for Newcells Biotech. After our successful fundraising in 2018, we went through a process of looking for individuals who had sector knowledge and leadership experience of growing life science companies. Frank will bring a unique insight to the Board to ensure we focus on a strategy that continues to deliver sustainable value to our customers engaged in drug discovery” Dr Mike Nicholds, CEO.

“It has been a real pleasure to welcome Frank on to the Newcells Board. His drive to add value along with his genuine excitement about our technology and plans for growth are already having an impact on our strategy discussions” Sandy Primrose, Chair

“Alongside his life science expertise, Frank Armstrong also has significant board experience making him an ideal candidate to join Newcells at an exciting time in their development. NVM are delighted with Frank’s appointment and believe he will be key to strengthening the business strategy and we are excited to be working with him on the next stage of Newcell’s journey.” Carmine Circelli, NVM private equity

In addition to his role at Newcells, Frank is Non-executive Chair of Summit Plc; Non-executive Chairman of Faron Pharmaceuticals Oy and Caldan Therapeutics Ltd; and a Member of the Strategic Advisory Board of HealthCare Royalty Partners and Epidarex Capital.

Frank’s career in the industry spans 30 years. He has worked in senior positions in Development in large Pharma companies and been the CEO of several private and public Biotech and Service Businesses in the UK, US and EU.

Frank received an honours degree in biochemistry and an MBChB(MD) in medicine from the University of Edinburgh in Scotland. He is a Fellow of the Royal College of Physicians, Edinburgh and a Fellow of the Faculty of Pharmaceutical Physicians.

You might also be interested in…

Development of functioning in vitro lung assay for modelling Covid-19 infection

Newcells Biotech, experts in induced pluripotent stem cell (iPSC) differentiation and assay construction, have confirmed their human lung epithelium model as an effective platform for modelling SARS-CoV-2 infection and replication.  Their work alongside the Liverpool School of Tropical Medicine (LTSM) Centre for Drugs and Diagnostics will be crucial in helping

The Biosphere

Newcells Biotech scales up its operations in The Biosphere

Newcells Biotech, a pioneering life-sciences spin-out that applies Human induced Pluripotent Stem Cells (hiPSCs) to develop assays for drug development, have consolidated their two laboratory sites into 500m2 of laboratory and co-located office space in The Biosphere, which forms part of the Newcastle Helix cluster.    The purpose-built space in the city centre site

COVID-19 Vaccine

An Overview of Vaccine Development & Sub-Types

Vaccination can be regarded as one of biomedicines biggest triumphs. Since Edward Jenner pioneered the smallpox vaccine in 1798, subsequent morbidity and mortality rates have declined for a multitude of diseases, such as Diphtheria, Whooping Cough and Measles.1 However, despite the success of these global vaccination